Evidence map›Paper›PMID 31497354›Full record

ArticleAmerican journal of cancer research2019

Wild-type

Chen Zhang, Emmanuel Martinez-Ledesma, Feng Gao, Wei Zhang, Jie Ding, Shaofang Wu, Xiaolong Li, Jimin Wu, Ying Yuan, Dimpy Koul and 1 more

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in American journal of cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Chen ZhangDepartment of Neuro-Oncology, Brain Tumor Center, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Emmanuel Martinez-LedesmaDepartment of Neuro-Oncology, Brain Tumor Center, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Feng GaoDepartment of Neuro-Oncology, Brain Tumor Center, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Wei ZhangDepartment of Neuro-Oncology, Brain Tumor Center, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Jie DingDepartment of Neuro-Oncology, Brain Tumor Center, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Shaofang WuDepartment of Neuro-Oncology, Brain Tumor Center, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Xiaolong LiDepartment of Neuro-Oncology, Brain Tumor Center, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Jimin WuDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Ying YuanDepartment of Biostatistics, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
Dimpy KoulDepartment of Neuro-Oncology, Brain Tumor Center, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
W K Alfred YungDepartment of Neuro-Oncology, Brain Tumor Center, The University of Texas MD Anderson Cancer Center Houston, TX, USA.
The University of Texas MD Anderson Cancer Center · USBeijing Tian Tan Hospital · CN

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo · 2008 to 2026
$41.2M
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA127001
6 · The paper itself

Abstract

Glioblastoma (GBM) is the most common and lethal primary intracranial tumor. Aggressive surgical resection plus radiotherapy and temozolomide have prolonged patients' median survival to only 14.6 months. Therefore, there is a critical need to develop novel therapeutic strategies for GBM. In this study, we evaluated the effect of NOTCH signaling intervention by gamma-secretase inhibitors (GSIs) on glioma sphere-forming cells (GSCs). GSI sensitivity exhibited remarkable selectivity among wild-type

Indexed as

gamma-secretase inhibitorGlioblastomaNOTCH signalingTP53

Identifiers

PMID31497354
PMCPMC6726980
OpenAlexW2983926736

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.